Genscript Biotech Zukünftiges Wachstum
Future Kriterienprüfungen 3/6
Genscript Biotech wird ein jährliches Gewinn- und Umsatzwachstum von 97.9% bzw. 5.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 97.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 8.3% betragen.
Wichtige Informationen
97.9%
Wachstumsrate der Gewinne
97.35%
EPS-Wachstumsrate
| Life Sciences Gewinnwachstum | 41.0% |
| Wachstumsrate der Einnahmen | 5.1% |
| Zukünftige Eigenkapitalrendite | 8.33% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 25 Apr 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Narrativ-Update • May 12
1548: European mRNA Expansion Will Support Future Upside Potential
Analysts have kept their HK$17.67 price target for Genscript Biotech broadly unchanged, with only slight tweaks to the discount rate and future P/E assumptions shaping this latest narrative update. What's in the News GenScript plans to put amendments to its fourth amended and restated memorandum and articles of association to a shareholder vote at the AGM on June 5, 2026, and proposes adopting a fifth amended and restated version of these governing documents (Key Developments).Narrativ-Update • Apr 24
1548: European mRNA Expansion And AI Integration Will Support Future Upside Potential
Analysts have trimmed their price target for Genscript Biotech to about HK$17.67 from roughly HK$18.56, citing slightly lower fair value estimates and a modestly reduced future P/E assumption, while keeping revenue growth and profit margin expectations broadly unchanged. What's in the News GenScript opened its first European mRNA production site in Delft, the Netherlands, expanding its mRNA platform and reinforcing Europe as a core part of its integrated R&D and production network (Key Developments).Narrativ-Update • Apr 10
1548: European mRNA Expansion And AI Integration Will Support Future Upside Potential
Analysts have slightly adjusted their view on Genscript Biotech, trimming the implied fair value from about HK$18.95 to around HK$18.56 as they fine tune assumptions on revenue growth, profit margin and future P/E levels. What's in the News Genscript opened its first European mRNA production site in Delft, the Netherlands, adding gene design, synthesis, vector engineering, IVT mRNA production, GenCap mRNA capping, UTR optimization and formulation support within a single facility (Key Developments).
Neues Narrativ • Mar 31
Heavy Automation Costs And Legend Exposure Will Slowly Give Way To Healthier Margins
Catalysts About Genscript Biotech Genscript Biotech is a global biotech group focused on gene to protein research tools, biologics CRDMO services and industrial enzyme products. What are the underlying business or industry changes driving this perspective?Narrativ-Update • Mar 25
1548: European mRNA Expansion Will Support Ongoing Upside Potential
Analysts have trimmed their HK$ price target on Genscript Biotech from about HK$22.12 to around HK$18.95, citing updated assumptions for slower revenue growth, a higher profit margin profile, and a lower future P/E multiple in their models. What's in the News GenScript opened its first European mRNA production site in Delft, the Netherlands, expanding its global mRNA platform with end to end capabilities that include gene design, vector engineering, IVT mRNA production, GenCap mRNA capping technology, UTR optimization, and formulation support (Key Developments).Narrativ-Update • Mar 10
1548: Higher Future P/E Assumptions Will Support Ongoing Upside Potential
Analysts have adjusted their HK$ price target for Genscript Biotech to reflect updated views on discount rate, long term profit margins and a higher assumed future P/E multiple. This has resulted in a modest recalibration of fair value rather than a wholesale shift in the investment case.Narrativ-Update • Feb 23
1548: Slightly Lower Future P/E Will Still Support Attractive Upside Potential
Analysts have trimmed their price target on Genscript Biotech to reflect a slightly lower assumed future P/E multiple, while keeping fair value broadly unchanged at about HK$22.12. They cite fine tuning of discount rate and margin assumptions rather than any major shift in the core outlook.Narrativ-Update • Feb 09
1548: Higher Discount Rate Will Still Support Attractive Future Upside Potential
Analysts have trimmed their fair value estimate for Genscript Biotech from $23.52 to $22.12, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. What's in the News Genscript Biotech held an Analyst/Investor Day, giving the market a closer look at its business, capital plans, and the assumptions that feed into analyst models (Key Developments).Analyseartikel • Nov 03
Unpleasant Surprises Could Be In Store For Genscript Biotech Corporation's (HKG:1548) Shares
With a median price-to-sales (or "P/S") ratio of close to 5.5x in the Life Sciences industry in Hong Kong, you could be...Analyseartikel • Oct 10
Is Genscript Biotech Corporation (HKG:1548) Trading At A 44% Discount?
Key Insights Genscript Biotech's estimated fair value is HK$30.13 based on 2 Stage Free Cash Flow to Equity Genscript...Analyseartikel • Sep 18
We Think You Can Look Beyond Genscript Biotech's (HKG:1548) Lackluster Earnings
The market for Genscript Biotech Corporation's ( HKG:1548 ) shares didn't move much after it posted weak earnings...Analyseartikel • Sep 08
Genscript Biotech (HKG:1548) Has A Pretty Healthy Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Narrativ-Update • Aug 21
Global Demand Rebound Will Drive Life Sciences And CDMO Expansion
Despite a sharp decline in consensus revenue growth forecasts and a substantial jump in future P/E, analysts have raised Genscript Biotech's fair value estimate from HK$21.61 to HK$23.01. What's in the News GenScript Biotech launched a new global brand platform, "Scripting Possibilities," alongside a refreshed visual identity and expanded marketing initiatives to drive growth and strengthen global brand presence.Analyseartikel • Jul 29
Genscript Biotech Corporation's (HKG:1548) 28% Price Boost Is Out Of Tune With Revenues
Genscript Biotech Corporation ( HKG:1548 ) shares have continued their recent momentum with a 28% gain in the last...Analyseartikel • Jul 24
At HK$18.16, Is It Time To Put Genscript Biotech Corporation (HKG:1548) On Your Watch List?
Genscript Biotech Corporation ( HKG:1548 ), might not be a large cap stock, but it saw a significant share price rise...Neues Narrativ • Jul 17
Global Demand Rebound Will Drive Life Sciences And CDMO Expansion
Expansion in global markets, technology upgrades, and industry partnerships are set to drive stronger growth, improved margins, and long-term earnings stability.Analyseartikel • May 14
Does Genscript Biotech (HKG:1548) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • Apr 07
Genscript Biotech Corporation (HKG:1548) May Have Run Too Fast Too Soon With Recent 27% Price Plummet
Genscript Biotech Corporation ( HKG:1548 ) shares have retraced a considerable 27% in the last month, reversing a fair...Analyseartikel • Feb 12
Investors Still Aren't Entirely Convinced By Genscript Biotech Corporation's (HKG:1548) Revenues Despite 27% Price Jump
Genscript Biotech Corporation ( HKG:1548 ) shares have had a really impressive month, gaining 27% after a shaky period...Analyseartikel • Jan 20
Genscript Biotech Corporation (HKG:1548) Shares Could Be 49% Below Their Intrinsic Value Estimate
Key Insights The projected fair value for Genscript Biotech is HK$19.29 based on 2 Stage Free Cash Flow to Equity...Analyseartikel • Nov 19
Market Still Lacking Some Conviction On Genscript Biotech Corporation (HKG:1548)
It's not a stretch to say that Genscript Biotech Corporation's ( HKG:1548 ) price-to-sales (or "P/S") ratio of 2.9x...Analyseartikel • Oct 01
Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • Sep 16
What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?
Genscript Biotech Corporation ( HKG:1548 ), might not be a large cap stock, but it received a lot of attention from a...Analyseartikel • Aug 02
After Leaping 44% Genscript Biotech Corporation (HKG:1548) Shares Are Not Flying Under The Radar
Genscript Biotech Corporation ( HKG:1548 ) shares have had a really impressive month, gaining 44% after a shaky period...Analyseartikel • Jun 05
Slammed 28% Genscript Biotech Corporation (HKG:1548) Screens Well Here But There Might Be A Catch
Unfortunately for some shareholders, the Genscript Biotech Corporation ( HKG:1548 ) share price has dived 28% in the...Analyseartikel • May 10
A Look At The Fair Value Of Genscript Biotech Corporation (HKG:1548)
Key Insights The projected fair value for Genscript Biotech is HK$14.11 based on 2 Stage Free Cash Flow to Equity With...Analyseartikel • Apr 13
Is Genscript Biotech (HKG:1548) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analyseartikel • Mar 13
Investors Appear Satisfied With Genscript Biotech Corporation's (HKG:1548) Prospects As Shares Rocket 29%
Genscript Biotech Corporation ( HKG:1548 ) shareholders are no doubt pleased to see that the share price has bounced...Analyseartikel • Jan 26
Genscript Biotech Corporation (HKG:1548) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Genscript Biotech Corporation ( HKG:1548 ) shareholders that were waiting for something to happen have been dealt a...Analyseartikel • Nov 21
Is Genscript Biotech (HKG:1548) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Aug 22
Is Genscript Biotech (HKG:1548) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • Apr 04
Time To Worry? Analysts Just Downgraded Their Genscript Biotech Corporation (HKG:1548) Outlook
The analysts covering Genscript Biotech Corporation ( HKG:1548 ) delivered a dose of negativity to shareholders today...Analyseartikel • Apr 03
Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report
It's been a mediocre week for Genscript Biotech Corporation ( HKG:1548 ) shareholders, with the stock dropping 10% to...Analyseartikel • Apr 02
Is Genscript Biotech (HKG:1548) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 1,045 | 360 | 239 | 388 | 6 |
| 12/31/2027 | 931 | 219 | 134 | 133 | 7 |
| 12/31/2026 | 816 | 75 | 127 | 176 | 7 |
| 12/31/2025 | 960 | -533 | 242 | 326 | N/A |
| 9/30/2025 | 894 | -264 | 184 | 277 | N/A |
| 6/30/2025 | 828 | 5 | 126 | 228 | N/A |
| 3/31/2025 | 711 | -31 | 2 | 152 | N/A |
| 12/31/2024 | 594 | -67 | -121 | 76 | N/A |
| 6/30/2024 | 454 | 419 | -276 | -20 | N/A |
| 3/31/2024 | 507 | 421 | -410 | -153 | N/A |
| 12/31/2023 | 560 | 423 | -543 | -287 | N/A |
| 9/30/2023 | 773 | -140 | -506 | -266 | N/A |
| 6/30/2023 | 707 | -185 | -523 | -245 | N/A |
| 3/31/2023 | 667 | -206 | -431 | -183 | N/A |
| 12/31/2022 | 626 | -227 | -339 | -120 | N/A |
| 9/30/2022 | 598 | -315 | -321 | -142 | N/A |
| 6/30/2022 | 570 | -403 | -304 | -163 | N/A |
| 3/31/2022 | 530 | -381 | -289 | -150 | N/A |
| 12/31/2021 | 490 | -359 | -274 | -137 | N/A |
| 9/30/2021 | 483 | -265 | -265 | -127 | N/A |
| 6/30/2021 | 454 | -183 | -256 | -118 | N/A |
| 3/31/2021 | 422 | -194 | -268 | -134 | N/A |
| 12/31/2020 | 391 | -205 | -279 | -151 | N/A |
| 9/30/2020 | 354 | -194 | -171 | -48 | N/A |
| 6/30/2020 | 318 | -183 | -64 | 54 | N/A |
| 3/31/2020 | 296 | -140 | -103 | 12 | N/A |
| 12/31/2019 | 273 | -97 | -142 | -30 | N/A |
| 9/30/2019 | 257 | -59 | N/A | -116 | N/A |
| 6/30/2019 | 241 | -22 | N/A | -202 | N/A |
| 3/31/2019 | 236 | 0 | N/A | 53 | N/A |
| 12/31/2018 | 231 | 21 | N/A | 308 | N/A |
| 9/30/2018 | 216 | 24 | N/A | 338 | N/A |
| 6/30/2018 | 201 | 27 | N/A | 369 | N/A |
| 3/31/2018 | 177 | 26 | N/A | 195 | N/A |
| 12/31/2017 | 153 | 26 | N/A | 21 | N/A |
| 9/30/2017 | 139 | 27 | N/A | 24 | N/A |
| 6/30/2017 | 125 | 28 | N/A | 27 | N/A |
| 3/31/2017 | 120 | 27 | N/A | 30 | N/A |
| 12/31/2016 | 115 | 26 | N/A | 33 | N/A |
| 9/30/2016 | 107 | 26 | N/A | 29 | N/A |
| 6/30/2016 | 99 | 25 | N/A | 25 | N/A |
| 3/31/2016 | 93 | 21 | N/A | 22 | N/A |
| 12/31/2015 | 87 | 18 | N/A | 20 | N/A |
| 9/30/2015 | 82 | 13 | N/A | 18 | N/A |
| 6/30/2015 | 78 | 8 | N/A | 16 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: 1548 wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (3%).
Ertrag vs. Markt: 1548 wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.
Hohe Wachstumserträge: 1548 wird voraussichtlich in den nächsten 3 Jahren rentabel werden.
Einnahmen vs. Markt: 1548Die Einnahmen des Unternehmens (5.1% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Hong Kong (8.7% pro Jahr).
Hohe Wachstumseinnahmen: 1548Die Einnahmen des Unternehmens (5.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: 1548Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (8.3%).
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/23 01:45 |
| Aktienkurs zum Tagesende | 2026/05/22 00:00 |
| Gewinne | 2025/12/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Genscript Biotech Corporation wird von 12 Analysten beobachtet. 7 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Jin Zhang | China International Capital Corporation Limited |
| Zhu Chen | Citic Securities Co., Ltd. |
| Wai Chak Yuen | Daiwa Securities Co. Ltd. |